TE
NTLA icon

Tema ETFs’s Intellia Therapeutics NTLA Stock Holding History

Tema ETFs’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Sell
13,708
-368
-3% -$5.15K 0.01% 510
2026
Q1 		$180K Sell
14,076
-184
-1% -$2.34K 0.01% 488
2025
Q4 		$128K Sell
14,260
-460
-3% -$6.33K 0.01% 520
2025
Q3 		$254K Sell
14,720
-9,333
-39% -$115K 0.02% 487
2025
Q2 		$226K Sell
24,053
-2,484
-9% -$20.4K 0.06% 161
2025
Q1 		$189K Sell
26,537
-121,630
-82% -$1.23M 0.06% 141
2024
Q4 		$1.73M Buy
+148,167
New +$2.31M 0.72% 42

Other funds holding NTLA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return

Tema ETFs's NTLA Position: Q2 2026 in Review

Tema ETFs reduced its Intellia Therapeutics (NTLA) stake by 2.6% in Q2 2026, selling an estimated $5.15K and leaving 13,708 shares worth $232K. The position accounts for 0.01% of the portfolio, ranked #510.

Tema ETFs first reported a position in NTLA in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.73M in Q4 2024. 23 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Tema ETFs held 13,708 shares of Intellia Therapeutics worth $232K as of Q2 2026.
  • Tema ETFs sold 368 Intellia Therapeutics shares in Q2 2026, an estimated $5.15K.
  • Intellia Therapeutics made up 0.01% of Tema ETFs's portfolio in Q2 2026, its #510 holding.
  • Tema ETFs first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Tema ETFs's Intellia Therapeutics position peaked at $1.73M in Q4 2024.
  • 23 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Tema ETFs's 13F filing for Q2 2026, filed 10 Jul 2026.